首页 | 本学科首页   官方微博 | 高级检索  
检索        


The role of thrombin receptors PAR1 and PAR4 for PAI-1 storage, synthesis and secretion by human platelets
Authors:Nylander Martina  Osman Abdimajid  Ramström Sofia  Aklint Emma  Larsson Anders  Lindahl Tomas L
Institution:
  • a Department of Clinical and Experimental Medicine, Linköping University, Sweden
  • b Department of Medical Sciences, University Hospital, Uppsala, Sweden
  • Abstract:

    Introduction

    Arterial thrombi contain more platelets than venous thrombi and are more resistant to fibrinolysis. This resistance could partly be due to plasminogen activator inhibitor 1 (PAI-1) secreted by platelets. The aim of this study was to elucidate differences between thrombin receptors protease-activated receptor (PAR) 1 and 4 and platelet storage, secretion and synthesis of platelet PAI-1, as compared to other platelet α-granule proteins such as VEGF and endostatin.

    Materials and methods

    Human isolated platelets were incubated with thrombin (0.5 U/ml), PAR1-activating peptide (AP) (0.4-30 μM) or PAR4-AP (1.5-300 μM) for up to 24 hours. ELISA, western blot and fluorescence microscopy were used to measure secretion, contents and localization of PAI-1, VEGF and endostatin.

    Results

    Our results show that PAI-1 and VEGF might be co-localized and that endostatin does not co-localize with either PAI-1 or VEGF. PAI-1 and VEGF show a similar secretion pattern, being more sensitive to low grade PAR1 activation, but secretion was also observed with higher concentrations of PAR4-APs. PAI-1 is secreted in an active form. PAI-1 mRNA was found in platelets, and elevated levels of PAI-1 were detected after 24 hours incubation of platelets.

    Conclusions

    PAI-1 and VEGF, but not endostatin, might be stored in the same α-granule in human platelets. PAI-1 and VEGF also show a similar secretion pattern, being more sensitive to PAR1 than to PAR4 activation, but the secretion is not exclusively selective. Our results also show that platelet PAI-1 is increased if incubated for 24 hours, both with addition of PAR1-activating peptide and without activation, which could indicate de novo synthesis.
    Keywords:Ab  antibody  CD  Acid citrate dextrosel  ADP  adenosine diphosphate  ATP  adenosine triphosphate  PAR4-AP  PAR4-activating peptide (amino acid sequence: AYPGKF)  ELISA  Enzyme-linked Immunosorbent Assay  GAPDH  glyceraldehyde 3-phosphate dehydrogenase  KRG  Krebs-Ringer glucose solution  mRNA  messenger Ribonucleic acid  PAI-1  plasminogen activator inhibitor-1  PAR1  protease-activated receptor 1  PAR4  protease-activated receptor 4  PDGF  platelet-derived growth factor  PRP  platelet rich plasma  SDS  sodium dodecyl sulphate  PAR1-AP  PAR1-activating peptide (amino acid sequence: SFLLRN)  tPA  tissue plasminogen activator  VEGF  vascular endothelial growth factor
    本文献已被 ScienceDirect PubMed 等数据库收录!
    设为首页 | 免责声明 | 关于勤云 | 加入收藏

    Copyright©北京勤云科技发展有限公司  京ICP备09084417号